Life Science manufacturing data management has become increasingly difficult with advancements in complex biopharma and “precision” cell and gene therapies. Meanwhile, with performance metrics in manufacturing lagging behind those in other pharma operations, there’s a demand for accelerated tech transfer, FDA filings and commercialization. There are new business demands for information to be processed faster.
In the life science industry, like many sectors, Excel is a proverbial hammer. However, not all problems are nails. Launched by Microsoft in the 80s, Excel has become ubiquitous as a tool for every department and workflow imaginable, ad hoc analyses, back-of-the-envelope calculations and more.
Successful technology transfer is reliant on a few key variables including robust process characterization and communication and collaboration among multiple teams and sites. The key determinant to achieving success is the exchange of accurate, compliant data in relevant time.
Therapies are more complex, tailored and varied than ever and the associated amount of data is growing – which requires a new level of attention to detail.
Trying to manually record experimental data while handling animals, reagents or working in sterile conditions can be challenging. Yes, recording your data is non-negotiable but does it have to be so cumbersome? Not anymore! See how IDBS has partnered with…
In the quest to develop the science and raise funding, developing a digital strategy in general is an afterthought for fledgling biotech companies – if it’s considered at all. Not paying attention to it early, however, can hamper their ability to advance their science and constrain their revenue-generation options.
IDBS will be presenting at the conference this year in Vienna. We look forward to being back at Bioprocess in-person events in 2022.
Skyland PIMS Democratizes Batch Data Management for AAV Gene Therapies and Accelerates CMO Collaboration
Leveraging multiple external partners, a leading clinical-stage biotechnology company manufactures AAV viral vectors as part of its proprietary gene delivery platform.
A legacy system approach isn’t suitable for modern BioPharma development. Here are four reasons why.
Modern BioPharma development requires more than just a LIMS and spreadsheets. Learn why in this article by Alberto Pascual, IDBS, featuring Accenture and published in Lab Manager.